Takeda to Acquire GammaDelta to Advance the Development of Allogeneic γδT Cell Therapies for the Treatment of Solid Tumors
Shots: Takeda exercises its option to acquire GammaDelta which includes up front along with development and regulatory milestones. The acquisition is expected to be close in Q1’22 The acquisition follows a 2017 collaboration b/w Takeda & GammaDelta to develop GammaDelta’s novel γδ T cell therapy platforms. Takeda will obtain GammaDelta’s allogeneic Vδ1 gamma-delta (γδ) T […]